Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
961 to 980 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering. | Int J Mol Sci | 2022 | 36499057 | PubTator, text mining | PubMed |
| Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors. | Cancers (Basel) | 2022 | 36497465 | PubTator, text mining | PubMed |
| The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology. | Cells | 2022 | 36497148 | PubTator, text mining | PubMed |
| Cellular therapy for multiple myeloma: what's now and what's next. | Hematology Am Soc Hematol Educ Program | 2022 | 36485132 | PubTator, text mining | PubMed |
| The application of mechanobiotechnology for immuno-engineering and cancer immunotherapy. | Front Cell Dev Biol | 2022 | 36483679 | PubTator, text mining | PubMed |
| CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. | Front Immunol | 2022 | 36483567 | PubTator, text mining | PubMed |
| Multiplexed engineering and precision gene editing in cellular immunotherapy. | Front Immunol | 2022 | 36483551 | PubTator, text mining | PubMed |
| Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning. | Science | 2022 | 36480602 | PubTator, text mining | PubMed |
| Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches. | Onco Targets Ther | 2022 | 36474506 | PubTator, text mining | PubMed |
| Identification of RNA N6-methyladenosine regulation in epilepsy: Significance of the cell death mode, glycometabolism, and drug reactivity. | Front Genet | 2022 | 36468034 | PubTator, text mining | PubMed |
| An In Vitro Comparison of Costimulatory Domains in Chimeric Antigen Receptor T Cell for Breast Cancer Treatment. | J Immunol Res | 2022 | 36457849 | PubTator, text mining | PubMed |
| Phase I CAR-T Clinical Trials Review. | Anticancer Res | 2022 | 36456127 | PubTator, text mining | PubMed |
| A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma. | Front Oncol | 2022 | 36439517 | PubTator, text mining | PubMed |
| Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis. | Front Oncol | 2022 | 36439485 | PubTator, text mining | PubMed |
| A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT). | Front Oncol | 2022 | 36439452 | PubTator, text mining | PubMed |
| Genomic Profiling of Sarcomas: A Promising Weapon in the Therapeutic Arsenal. | Int J Mol Sci | 2022 | 36430703 | PubTator, text mining | PubMed |
| CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro. | Cells | 2022 | 36429120 | PubTator, text mining | PubMed |
| Current Developments in Cellular Therapy for Castration Resistant Prostate Cancer: A Systematic Review of Clinical Studies. | Cancers (Basel) | 2022 | 36428811 | PubTator, text mining | PubMed |
| Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox. | Cancers (Basel) | 2022 | 36428748 | PubTator, text mining | PubMed |
| Current and Future Perspectives for Chimeric Antigen Receptor T Cells Development in Poland. | Biomedicines | 2022 | 36428480 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=49